Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapyBoaz Wong, Jean‐Simon Diallo|Molecular Therapy|2023Cited by 23
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergyRozanne Arulanandam, Jean‐Simon Diallo|Communications Biology|2020Cited by 16
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Jean‐Simon Diallo|Nature Communications|2024Cited by 14
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirusZaid Taha, Jean‐Simon Diallo|Frontiers in Immunology|2023Cited by 11